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PDGFRAAbstract Basaloid squamous cell carcinoma of esophagus (BSCC-E) is rare. This case report is the
first demonstrating KIT protein expression of BSCC-E. A 74-year-old man presented with
dysphagia. Endoscopy revealed a polypoid tumor (2 × 2 × 2.5 cm) with a stalk in cervical
esophagus. Biopsy showed squamous cell carcinoma with undifferentiated areas. An endoscopic
submucosal dissection (ESD) was performed. Grossly, it was solid tumor with white cut surface.
Histologically, the tumor was hypercellular carcinoma consisting of solid areas of island. The
tumor cells were composed of basaloid malignant cells with hyperchromatic nuclei, scant
cytoplasm, and basophilic cytoplasm. Many mitotic figures were recognized. Foci of
comedonecrosis were scattered. Areas of squamous and glandular differentiations were scattered.
Immunohistochemically, the tumor cells were positive for pancytokeratin (PCK) CAM5.2, PCK
AE1/3, cytokeratin (CK) 7, KIT, CEA, CA19-9, EMA, Ki-67 (labeling index = 80%). The tumor
cells were negative for CK20, PDGFRA, NSE, vimentin, estrogen receptor, p53 protein,
chromogranin, synaptophysin, CD56, and TTF-1.
© 2014 The Author. Published byElsevier Inc. This is an open access article under theCCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction [1]. A review of English literature by PubMed search revealedBasaloid squamous cell carcinoma (BSCC) of esophagus
(BSCC-E) is a rare malignant neoplasm. It is morphologically
characterized by basal cell carcinoma-like squamous cell
carcinoma frequently showing glandular differentiation and
comedonecrosis [1]. The cells of BSCC have hyperchromatic
nuclei increased nucleo-cytoplasmic ratio, and basophilic
cytoplasm, thus resembling basal cell carcinoma of the skin⁎ Tel.: +81 54 336 1111; fax: +81 54 336 1315.
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censes/by-nc-nd/3.0/).about 50 case reports or case series of BSCC-E [2,3] and
about 10 case reports or case series with immunohistochem-
ical study [1,4,5]. However, there are no reports of the protein
expression and gene mutational status of KIT (CD117) and
platelet-derived growth factor-α (PDGFRA) in BSCC-E.
KIT and PDGFRA genes, both mapped to 4q12, encode
receptor tyrosine kinase oncoproteins called KIT (CD117)
and PDGFRA, respectively [6–11]. Both molecules are
transmembranous oncoproteins involved in tumorigenesis
of some neoplasms including gastrointestinal stromal tumor
(GIST), acute myeloid leukemia, mast cell neoplasms, germess article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 2 Gross pathologic findings. The polyp is solid tumor
with white cut surface.
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large cell neuroendocrine carcinoma (LCNEC), adenoid
cystic carcinoma (ACC), small cell lung carcinoma
(SCLC), and extra-pulmonary small cell carcinoma
(SmCC) [12–27]. The hot spots of gene mutations are
exons 9, 11, 13, and 17 of KIT gene and exons 12 and 18 of
PDGFRA gene [6–11].
Herein, reported is a case of BSCC-E with protein
expression of KIT but without protein expression of
PDGFRA. A genetic analysis revealed no mutations of the
KIT and PDGFRA genes.
2. Case report
A 74-year-old man presented with dysphagia and
anemia. Blood test revealed anemia (red blood cells
282 × 104/μl, normal 450–550 × 104/μl), high creatinine
(1.32 mg/dl, normal 0.4–1.2), high C-reactive protein
(5.72 mg/dl, normal 0–0.3), and low Fe (17 μg/dl, normal
54–200). The serum tumor markers showed elevated SCC
(2.0 ng/ml, normal 0–1.5). Serum CEA was within normal
ranges. Upper gastrointestinal endoscopy revealed a polyp-
oid tumor (2 × 2 × 2.5 cm) with a stalk in the cervical
esophagus (Fig. 1). The biopsy showed squamous cell
carcinoma with undifferentiated areas. Imaging modalities
(CT, PET, PET-CT, andMRI) showed no tumors other than
the esophageal tumor. Because the tumor was polypoid and
the biopsy showed no apparent invasion, an endoscopic
submucosal dissection (ESD) of the polypoid tumor was
performed successfully.
Gross pathological examination showed that the tumor is
solid tumor with white cut surface (Fig. 2). Histologically,
the tumor is hypercellular carcinoma consisting of solid
areas of island (Fig. 3A). The tumor was continuous with
surface esophageal squamous epithelium which showedFig. 1 Esophageal endoscopy. A polyp with stalk is seen. The
polyp measures 2 × 2 × 2.5 cm.carcinomatous changes. The tumor cells were composed of
basaloid malignant cells with hyperchromatic nuclei, scant
cytoplasm, and basophilic cytoplasm (Fig. 3A, B, C and D).
Many mitotic figures were recognized. Characteristically,
foci of comedonecrosis were scattered (Fig. 3A and B).
Areas of squamous differentiation (Fig. 3C) and glandular
differentiation (Fig. 3D) were also scattered. The patholog-
ical diagnosis was BSCC of the esophagus. According to
WHO blue book [1], it was typical BSCC-E.
An immunohistochemical analysis was performed by the
Dako Envisionmethod (Dako Corp, Glostrup, Denmark), as
previously reported [28,29]. Immunohistochemically, the
tumor cells are positive for pancytokeratin (PCK) CAM5.2
(Fig. 4A), PCK AE1/3, cytokeratin (CK) 7, KIT (Fig. 4B),
CEA, CA19-9 (Fig. 4C), EMA, Ki-67 (labeling index =
80%) (Fig. 4D). The tumor cells were negative for CK20,
PDGFRA, neuron-specific enolase (NSE), vimentin, estro-
gen receptor, p53 protein, chromogranin, synaptophysin,
CD56, and TTF-1.
A molecular genetic analysis of KIT gene (exons 9,
11, 13, and 17) and PDGFRA (exons 12 and 18) gene
was performed by the PCR direct sequencing method, as
previously reported [12–27]. The exons of both genes
were selected because they are frequent mutation sites
[6–27]. In brief, genomic DNAwas extracted from paraffin
blocks with proteinase K digestion and phenol/chloroform
extraction, and subjected to PCR for 40 cycles (94 °C for
one minute, 52 °C for one minute, 72 °C for one minute),
using a thermal cycler (GeneAmp PCR system 9700,
Applied Biosystems, ABI, CA). The annealing temperature
was 53 °C. PCR products were extracted, and subjected to a
computed automatic DNA sequencer (ABI PRIZM 3100
Genetic Analyzer, Applied Biosystems, ABI, CA).
The retrospective genetic analysis using PCR-direct
sequencing method in paraffin sections identified no
mutations of KIT (exons 9, 11, 13 and 17) and PDGFRA
(exons 12 and 18) genes in the present tumor.
After the ESD, re-endoscopy was performed, and it did
not reveal tumor. However, biopsy showed a few carcinoma
Fig. 3 HE histologies of esophageal basaloid squamous cell carcinoma. A: Very low power view. The tumor is cellular medullary
tumor consisting of basaloid carcinoma cells. Comedonecrosis is seen. HE, ×20. B: Intermediate power view. The characteristic basaloid
tumor cells, comedonecrosis, and glandular differentiation are apparent. HE, ×100. C: High power view. The squamous differentiation is
obvious. HE, ×200. D: High power view. The glandular differentiation is apparent. HE, ×200.
42 T. Teradacells; the lesion was burned. The third biopsy showed no
residual tumor. Now, the patient is free from tumor by
endoscopy and various imaging techniques 9 months after
the first ESD, and is followed-up.Fig. 4 Immunohistochemical findings of the tumor cells. The tumor
(B), CA19-9 (C), and Ki-67 (labeling index = 80%) (D). The expression3. Discussion
The present case is the first of esophageal BSCC with
examination of immunoreactive KIT (CD117) andcells are positive for pancytokeratin CAM5.2 (A), KIT (CD117)
of KIT is membranous. Immunostainings. A, D: ×200. B, C: ×400.
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and PDGFRA genes. The present case showed that the
tumor cells of esophageal BSCC expressed KIT protein but
not PDGFRA protein. No mutations of KIT (exons 9, 11,
13, and 17) and PDGFRA (exons 12 and 18) genes were
recognized. Although the genetic analysis is narrow, these
seem new findings.
In the head and neck region, adenoid cystic carcinoma
(ACC) is famous for positive KIT protein [6,8,9]. From
the findings of the current case, it can be stressed that
BSCC of esophagus is included into KIT-positive
neoplasms in addition to ACC. In KIT-positive ACC, no
mutations of KIT is seen [6,8,9], similar to the current
case. To the best of author's knowledge, there have been
no studies of PDGFRA protein and gene mutational status
in ACC. The present case showed that BSCC of the
esophagus did not show PDGFRA protein expression and
PDGFRA gene mutation.
In the esophagus, small cell carcinoma (SmCC) is
known to express KIT and PDGFRA protein, but no
mutations of KIT and PDGFRA genes are seen in
esophageal small cell carcinoma [8,9]. Therefore, esoph-
ageal SmCC and BSCC-E are included into KIT-positive
neoplasms of the esophagus, in addition to ACC.
Positive immunoreaction of KIT and PDGFRA protein
does not necessary imply gene mutations of KIT and
PDGFRA. In general, KIT protein-positive tumors include
GIST, acute myeloid leukemia, mast cell neoplasms, germ
cell tumors, melanoma, neuroendocrine carcinomas
(NEC), large cell neuroendocrine carcinoma (LCNEC),
ACC, small cell lung carcinoma (SCLC), and extra-
pulmonary SmCC [12–27]. Of these neoplasms express-
ing KIT, KIT mutations are shown to be present in GIST
[6–11,20,22,24,30], germ cell tumors [18,21], and malig-
nant melanoma [19]. PDGFRA mutations are seen mainly
in GIST [6–11,22]. In contrast, neuroendocrine carcino-
mas [13], large cell neuroendocrine carcinomas [11,12],
ACC [6,8,9], SCLC [13,31,32], and extra-pulmonary
SmCC [12,14–20,24–27] are shown to express KIT and
PDGFRA proteins, but no mutations are seen in these
genes. Sihto et al. [31] insisted that KIT expression in
SCLC is due not to KIT gene mutations but to KIT gene
amplification. Other factors of KIT protein positivity and
no KIT gene mutations include enhanced transcription, as
distinct from increased tumor copy number, as well as
mRNA isoform stability changes which can be encoun-
tered in various tumors. Such a status may be operative in
KIT protein-positive but KIT gene mutation-negative
neoplasms such as SCLC, extra-pulmonary SmCC, ACC,
LC, and LCNEC. In the present BSCC of the esophagus
also, KIT expression may be due to KIT gene amplification
or other factors.
Recently, the phosphorylation (activation) status of
KIT and PDGFRA has been studies [30,33]. This isparticularly important in KIT mutation-negative tumors as
in the present case. KIT kinase activation and downstream
signaling proteins leading to tumorigenesis have been
studied, but little is known as yet. Protein kinase C-theta
and PI3-kinase/AKT are activated in imatinib-resistant
GIST [30], and analyses of these KIT signaling molecules
may be important in the treatment of GIST. Such studies
are not performed in SCC. In the present case, the author
could not investigate these molecules, because no relevant
antibodies were available. KIT tyrosine kinase activity and
KIT signaling abnormalities in SCC remain to be studied.
In the current case, the first biopsy was pathologically
diagnosed as squamous cell carcinoma with undifferentiated
areas. Therefore, it seems that the biopsy diagnosis of BSCC
of the esophagus is difficult. The present tumor showed
characteristic gross appearance, i.e., polyp with a stalk.
Fortunately, this feature made it easy for endoscopists to
remove the tumor. The patient finally underwent complete
resection of the esophageal BSCC. The patient is healthy
without any tumors in the body.
The pathological diagnosis of the current tumor seems
definite and typical, according to WHO [1]. The basaloid
malignant cells, focal squamous and glandular differenti-
ation, many mitotic figures, characteristic basaloid nature
of tumor cells, and spotty comedonecrosis are all
characteristic features of BSCC of esophagus [1]. The
present case is not pure SCC because it showed broad
areas of basaloid features.
An immunohistochemical study was performed in the
current case. The tumor cells are positive for PCK CAM5.2
andAE1/3, CK7, KIT, CEA, CA19-9, EMA,Ki-67 (labeling
index = 80%). In contrast, the tumor cells were negative for
CK20, PDGFRA, NSE, vimentin, estrogen receptor, p53
protein, chromogranin, synaptophysin, CD56, and TTF-1.
The positive reaction of PCK and CK7 shows epithelial
nature of the tumor. The positive reaction of CEA andCA19-
9 may imply that BSCC has glandular phenotypes although
they are thought to be irrelevant in immunohistochemically;
especially CEA and CA19-9 were accentuated in the
glandular differentiation areas of the current tumor. Positive
EMA may imply epithelial nature. The high Ki-67 labeling
(labeling index = 80%) may imply high cell proliferative
activity and relatively malignant nature of the present tumor.
The CK7+/CK20− pattern of the present tumor is
compatible with primary BSCC of esophagus. The negative
reaction of NSE, chromogranin, synaptophysin, and CD56
demonstrates that the present BSCC of the esophagus is
not NEC or that the current tumor shows no neuroendocrine
differentiation. The negative reaction of estrogen receptor
and TTF-1 imply that the current tumor has no relationship
to hormone producing tumors or lung adenocarcinoma. The
negative vimentin may indicate that the tumor is not
mesenchymal tumor. The present tumor was negative for
p53 protein, suggesting no p53 gene mutations.
44 T. TeradaIn summary, the author reported the first case of
esophageal BSCC expressing KIT. PDGFRA was not
expressed. A genetic analysis showed no mutations in the
KIT and PDGFRA genes. An immunohistochemical study
was performed.
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